Contacts

MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company

February 23, 2023

Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.

Rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector.

ISS, one of the world’s leading rating agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.

MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders.

The first product based on Medincell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipe of other products follows.

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.